Impact of IVIG therapy on serologic testing for infectious diseases

Kimberly E. Hanson, Nielsen Gabriel, Ian Mchardy, Wesley Hoffmann, Stuart H. Cohen, Marc Roger Couturier, George R. Thompson

Research output: Contribution to journalArticle

Abstract

Intravenous immunoglobulin (IVIG) is used to treat an increasing number of conditions. The anti-inflammatory and immunomodulatory effects of IVIG can be life-saving; however, recent administration may complicate evaluation for infection. To assess the impact of IVIG therapy on a variety of common viral, bacterial, fungal, and parasitic serologies we prospectively evaluated serologic changes pre- and post-IVIG infusion in 7 participants. The number of new antibody detections ranging from 2 to 5. New detections included positivity for Epstein–Barr virus early D antigen, herpes simplex virus, West Nile virus, cytomegalovirus, and the endemic mycoses Histoplasma and Coccidioides. The greatest number of newly positive serologies was observed in subjects receiving cumulative doses of IVIG in excess of 100 g. Our results illustrate the difficulty in serologic interpretation following IVIG therapy and suggest a dose–response to new positive results. These findings may be a helpful resource to clinicians facing similar circumstances.

Original languageEnglish (US)
Article number114952
JournalDiagnostic Microbiology and Infectious Disease
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Passive Immunization
Intravenous Immunoglobulins
Communicable Diseases
Serology
Coccidioides
Histoplasma
West Nile virus
Mycoses
Simplexvirus
Cytomegalovirus
Intravenous Infusions
Anti-Inflammatory Agents
Viruses
Antigens
Antibodies
Infection

Keywords

  • Infection
  • IVIG
  • Serology

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Impact of IVIG therapy on serologic testing for infectious diseases. / Hanson, Kimberly E.; Gabriel, Nielsen; Mchardy, Ian; Hoffmann, Wesley; Cohen, Stuart H.; Couturier, Marc Roger; Thompson, George R.

In: Diagnostic Microbiology and Infectious Disease, 01.01.2019.

Research output: Contribution to journalArticle

@article{39e39934245d4cc6ba5f1e71e825f204,
title = "Impact of IVIG therapy on serologic testing for infectious diseases",
abstract = "Intravenous immunoglobulin (IVIG) is used to treat an increasing number of conditions. The anti-inflammatory and immunomodulatory effects of IVIG can be life-saving; however, recent administration may complicate evaluation for infection. To assess the impact of IVIG therapy on a variety of common viral, bacterial, fungal, and parasitic serologies we prospectively evaluated serologic changes pre- and post-IVIG infusion in 7 participants. The number of new antibody detections ranging from 2 to 5. New detections included positivity for Epstein–Barr virus early D antigen, herpes simplex virus, West Nile virus, cytomegalovirus, and the endemic mycoses Histoplasma and Coccidioides. The greatest number of newly positive serologies was observed in subjects receiving cumulative doses of IVIG in excess of 100 g. Our results illustrate the difficulty in serologic interpretation following IVIG therapy and suggest a dose–response to new positive results. These findings may be a helpful resource to clinicians facing similar circumstances.",
keywords = "Infection, IVIG, Serology",
author = "Hanson, {Kimberly E.} and Nielsen Gabriel and Ian Mchardy and Wesley Hoffmann and Cohen, {Stuart H.} and Couturier, {Marc Roger} and Thompson, {George R.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.diagmicrobio.2019.114952",
language = "English (US)",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Impact of IVIG therapy on serologic testing for infectious diseases

AU - Hanson, Kimberly E.

AU - Gabriel, Nielsen

AU - Mchardy, Ian

AU - Hoffmann, Wesley

AU - Cohen, Stuart H.

AU - Couturier, Marc Roger

AU - Thompson, George R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Intravenous immunoglobulin (IVIG) is used to treat an increasing number of conditions. The anti-inflammatory and immunomodulatory effects of IVIG can be life-saving; however, recent administration may complicate evaluation for infection. To assess the impact of IVIG therapy on a variety of common viral, bacterial, fungal, and parasitic serologies we prospectively evaluated serologic changes pre- and post-IVIG infusion in 7 participants. The number of new antibody detections ranging from 2 to 5. New detections included positivity for Epstein–Barr virus early D antigen, herpes simplex virus, West Nile virus, cytomegalovirus, and the endemic mycoses Histoplasma and Coccidioides. The greatest number of newly positive serologies was observed in subjects receiving cumulative doses of IVIG in excess of 100 g. Our results illustrate the difficulty in serologic interpretation following IVIG therapy and suggest a dose–response to new positive results. These findings may be a helpful resource to clinicians facing similar circumstances.

AB - Intravenous immunoglobulin (IVIG) is used to treat an increasing number of conditions. The anti-inflammatory and immunomodulatory effects of IVIG can be life-saving; however, recent administration may complicate evaluation for infection. To assess the impact of IVIG therapy on a variety of common viral, bacterial, fungal, and parasitic serologies we prospectively evaluated serologic changes pre- and post-IVIG infusion in 7 participants. The number of new antibody detections ranging from 2 to 5. New detections included positivity for Epstein–Barr virus early D antigen, herpes simplex virus, West Nile virus, cytomegalovirus, and the endemic mycoses Histoplasma and Coccidioides. The greatest number of newly positive serologies was observed in subjects receiving cumulative doses of IVIG in excess of 100 g. Our results illustrate the difficulty in serologic interpretation following IVIG therapy and suggest a dose–response to new positive results. These findings may be a helpful resource to clinicians facing similar circumstances.

KW - Infection

KW - IVIG

KW - Serology

UR - http://www.scopus.com/inward/record.url?scp=85076057773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076057773&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2019.114952

DO - 10.1016/j.diagmicrobio.2019.114952

M3 - Article

C2 - 31787407

AN - SCOPUS:85076057773

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

M1 - 114952

ER -